These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 17904879

  • 1. T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant.
    Comoli P, Basso S, Labirio M, Baldanti F, Maccario R, Locatelli F.
    Blood Cells Mol Dis; 2008; 40(1):68-70. PubMed ID: 17904879
    [Abstract] [Full Text] [Related]

  • 2. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J, Einsele H, Gil L, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [Abstract] [Full Text] [Related]

  • 3. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M, Le Blanc K, Ringdén O, Barkholt L, Omazic B, Lergin C, Levitsky V, Remberger M.
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [Abstract] [Full Text] [Related]

  • 4. Adoptive T-cell transfer for refractory viral infections with cytomegalovirus, Epstein-Barr virus or adenovirus after allogeneic stem cell transplantation.
    Feucht J, Joachim L, Lang P, Feuchtinger T.
    Klin Padiatr; 2013 May; 225(3):164-9. PubMed ID: 23700092
    [Abstract] [Full Text] [Related]

  • 5. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development.
    Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A.
    Bone Marrow Transplant; 2006 Mar; 37(6):539-46. PubMed ID: 16462755
    [Abstract] [Full Text] [Related]

  • 6. Unmanipulated donor lymphocytes for EBV-related PTLD after T-cell depleted HLA-haploidentical transplantation.
    De Pasquale MD, Mastronuzzi A, De Vito R, Cometa A, Inserra A, Russo C, De Ioris MA, Locatelli F.
    Pediatrics; 2012 Jan; 129(1):e189-94. PubMed ID: 22144701
    [Abstract] [Full Text] [Related]

  • 7. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
    Micklethwaite K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M, Shaw P, Bradstock K, Gottlieb D.
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):707-14. PubMed ID: 17531781
    [Abstract] [Full Text] [Related]

  • 8. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
    Meijer E, Cornelissen JJ.
    Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
    [Abstract] [Full Text] [Related]

  • 9. Cytotoxic T lymphocytes for the treatment of viral infections and posttransplant lymphoproliferative disorders in transplant recipients.
    Pagliara D, Savoldo B.
    Curr Opin Infect Dis; 2012 Aug; 25(4):431-7. PubMed ID: 22614521
    [Abstract] [Full Text] [Related]

  • 10. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM, Crawford DH.
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [Abstract] [Full Text] [Related]

  • 11. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation.
    Kasow KA, Leung W, Horwitz EM, Woodard P, Handgretinger R, Hale GA.
    Pediatr Blood Cancer; 2007 Nov; 49(6):869-72. PubMed ID: 16421900
    [Abstract] [Full Text] [Related]

  • 12. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.
    Swinnen LJ.
    Best Pract Res Clin Haematol; 2006 Nov; 19(4):839-47. PubMed ID: 16997187
    [Abstract] [Full Text] [Related]

  • 13. T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients.
    Leen AM, Myers GD, Bollard CM, Huls MH, Sili U, Gee AP, Heslop HE, Rooney CM.
    Ann N Y Acad Sci; 2005 Dec; 1062():104-15. PubMed ID: 16461793
    [Abstract] [Full Text] [Related]

  • 14. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
    Sukdolak C, Tischer S, Dieks D, Figueiredo C, Goudeva L, Heuft HG, Verboom M, Immenschuh S, Heim A, Borchers S, Mischak-Weissinger E, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B.
    Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747
    [Abstract] [Full Text] [Related]

  • 15. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation.
    Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K, Handgretinger R, Peters C, Schuster FR, Beck R, Schumm M, Lotfi R, Jahn G, Lang P.
    Br J Haematol; 2006 Jul; 134(1):64-76. PubMed ID: 16803570
    [Abstract] [Full Text] [Related]

  • 16. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.
    Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, Martinez CA, Kennedy-Nasser A, Leung KS, Gottschalk SM, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM.
    Mol Ther; 2013 Nov; 21(11):2113-21. PubMed ID: 23783429
    [Abstract] [Full Text] [Related]

  • 17. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease.
    Uhlin M, Gertow J, Uzunel M, Okas M, Berglund S, Watz E, Brune M, Ljungman P, Maeurer M, Mattsson J.
    Clin Infect Dis; 2012 Oct; 55(8):1064-73. PubMed ID: 22806594
    [Abstract] [Full Text] [Related]

  • 18. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
    Dolcetti R.
    Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
    Sato E, Ohga S, Kuroda H, Yoshiba F, Nishimura M, Nagasawa M, Inoue M, Kawa K.
    Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
    [Abstract] [Full Text] [Related]

  • 20. Non-uniform in vivo Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease.
    Burns DM, Ryan GB, Harvey CM, Nagy E, Hughes S, Murray PG, Russell NH, Fox CP, Long HM.
    Front Immunol; 2019 Sep; 10():2489. PubMed ID: 31736946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.